Randomized phase II adjuvant trial of dose-dense docetaxel before or after doxorubicin plus cyclophosphamide in axillary node-positive breast cancer
| Autor: | Anne McVey, Mark Knapp, Taral Patel, Donn C. Young, Charles L. Shapiro, Mark E. Thompson, Ewa Mrozek, Susan Ottman, Shannon Puhalla, Nancy J. Merriman, Timothy David Moore, James F. Maher, Kari Kendra |
|---|---|
| Rok vydání: | 2008 |
| Předmět: |
Adult
Cancer Research medicine.medical_specialty Anthracycline Cyclophosphamide medicine.medical_treatment Urology Breast Neoplasms Docetaxel chemistry.chemical_compound Antineoplastic Combined Chemotherapy Protocols medicine Humans Doxorubicin Aged Chemotherapy Taxane Dose-Response Relationship Drug business.industry Middle Aged Nitrogen mustard Surgery Oncology chemistry Chemotherapy Adjuvant Lymphatic Metastasis Axilla Female Taxoids business Pegfilgrastim medicine.drug |
| Zdroj: | Journal of clinical oncology : official journal of the American Society of Clinical Oncology. 26(10) |
| ISSN: | 1527-7755 |
| Popis: | Purpose An anthracycline-based combination followed by, or combined with, a taxane is the sequence used in most adjuvant chemotherapy regimens. We hypothesized that administering the taxane before the anthracycline combination would be associated with fewer dose reductions and delays than the reverse sequence. To test this hypothesis, a randomized phase II multicenter adjuvant chemotherapy trial was performed. Patients and Methods Fifty-six patients with axillary node-positive, nonmetastatic breast cancer were randomly assigned either to group A (docetaxel [DOC] 75 mg/m2 intravenously [IV] every 14 days for four cycles followed by doxorubicin 60 mg/m2 and cyclophosphamide 600 mg/m2 [AC] IV every 14 days for four cycles); or to group B (AC followed by DOC) at the identical doses and schedule. Pegfilgrastim 6 mg subcutaneous injection was administered 1 day after the chemotherapy in all treatment cycles. The primary objective was to administer DOC without dose reductions or delays before or after AC and calculate the relative dose intensity (RDI) of DOC and AC. Results The majority of toxicities were grade 0 to 2 irrespective of sequence. The RDI for DOC was 0.96 and 0.82, respectively, in groups A (DOC followed by AC) and B (AC followed by DOC), with more frequent dose reductions occurring in group B (46% v 18%). The RDI for AC was 0.95 and 0.98 in groups A and B, respectively. Conclusion The administration of DOC before AC results in fewer DOC dose reductions and a higher RDI than the reverse sequence. Larger trials evaluating the sequence of DOC before anthracyclines are justified. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|